NCT04691570View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 10, 2021

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
DRUG

ANX005

ANX005 is provided as a solution for IV infusion

Trial Locations (1)

55905

Investigational Site 01, Rochester

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY

NCT04691570 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) | Biotech Hunter | Biotech Hunter